Anti-angiogenic therapy in ovarian cancer: A great expectation to be confi rmed

Clinical and Translational Oncology

Volumn 11, Issue 9, 2009, Pages 559-560

  Martín, Antonio González ^a  

^a Anderson International España   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

CARCINOMA; DRUG ADMINISTRATION; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; NOTE; OVARY TUMOR; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; VALIDATION STUDY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; TREATMENT OUTCOME; VALIDATION STUDIES AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73349120293     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-009-0404-0     Document Type: Editorial

References (9)

1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Bookman MA, Brady MF, McGuire WP et al (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol 27:1419-1425
3. González Martín A (2007) Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: A new standard in patient care? Clin Transl Oncol 9:409-411
4. Isonishi S, Yasuda M, Takahashi F et al (2008) Randomized phase III trial of conventional paclitaxel and carboplatin versus dose dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. J Clin Oncol 26[Suppl]:abstr 5506
5. Gómez-Raposo C, Mendiola M, Barriuso J et al (2009) Angiogenesis and ovarian cancerr. Clin Transl Oncol 11:564-571
6. Sánchez-Muñoz A, Pérez-Ruiz E, Mendiola Fernández C et al (2009) Current status of anti-angiogenic agents in the treatment of ovarian carcinoma. Clin Transl Oncol 11:589-595
7. Burger RA, Sill MW, Monk BJ et al (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25:5165-5171
8. Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platin-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186
9. Simpkins F, Belinson JL, Rose PG et al (2007) Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 107:118-123